FEMY · Femasys Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.29M | $1.63M | $1.07M | $1.21M | $1.04M |
| Cost of Revenue | $872.4K | $544.9K | $380.1K | $441.9K | $306.5K |
| Gross Profit | $1.42M | $1.08M | $691.9K | $764.3K | $731.4K |
| R&D | $7.58M | $8.22M | $7.21M | $5.81M | $4.13M |
| SG&A | $6.65M | $6.33M | $6.86M | $5.43M | $2.54M |
| Total Operating Expenses | $19.01M | $18.87M | $15.20M | $12.36M | $7.66M |
| D&A | $342.0K | $297.3K | $483.5K | $561.2K | $679.7K |
| Operating Income | ($17.59M) | ($17.79M) | ($14.51M) | ($11.60M) | ($6.93M) |
| Interest Expense | $1.89M | $1.60M | $165.4K | $13.5K | $12.6K |
| Income Tax | $1.3K | $9.6K | $4.3K | $6.3K | $1.8K |
| Net Income | ($18.63M) | ($18.82M) | ($14.25M) | ($11.39M) | ($6.91M) |
| EPS - Basic | ($0.47) | ($0.85) | ($0.93) | ($0.96) | ($7.20) |
| EPS - Diluted | ($0.47) | ($0.85) | ($0.93) | ($0.96) | ($7.20) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $9.27M | $3.45M | $21.72M | $12.96M | $24.78M |
| Accounts Receivable | $616.6K | $488.4K | $98.9K | $77.5K | $84.3K |
| Inventory | $5.74M | $3.05M | $667.1K | $436.7K | $208.3K |
| Accounts Payable | $1.83M | $1.42M | $1.14M | $510.8K | $445.5K |
| Current Assets | $16.46M | $8.02M | $23.18M | $14.13M | $25.63M |
| Total Assets | $20.72M | $12.45M | $27.76M | $16.90M | $28.58M |
| Current Liabilities | $3.64M | $8.58M | $3.05M | $1.53M | $1.69M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $14.85M | $10.14M | $9.40M | $1.65M | $2.24M |
| Stockholders' Equity | $5.87M | $2.30M | $18.35M | $15.24M | $26.33M |
| Retained Earnings | ($145.83M) | ($127.20M) | ($108.38M) | ($94.13M) | ($82.74M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($18.69M) | ($19.44M) | ($11.28M) | ($10.73M) | ($4.93M) |
| Investing Cash Flow | ($630.1K) | ($847.8K) | ($143.9K) | ($407.5K) | $968.3K |
| Financing Cash Flow | $25.14M | $2.03M | $20.18M | ($681.6K) | $871.6K |
| CapEx | $525.0K | $761.7K | $143.9K | $407.5K | $8.4K |
| Free Cash Flow | ($19.22M) | ($20.21M) | ($11.42M) | ($11.14M) | ($4.94M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 62.0% | 66.6% | 64.5% | 63.4% | 70.5% |
| Operating margin | -767.0% | -1091.8% | -1353.4% | -961.7% | -668.0% |
| EBITDA margin | -752.0% | -1073.5% | -1308.3% | -915.2% | -602.5% |
| Net margin | -812.3% | -1155.0% | -1329.1% | -944.6% | -666.2% |
| Free cash flow margin | -837.9% | -1240.3% | -1065.7% | -923.5% | -476.1% |
| FCF / Net income | 1.03 | 1.07 | 0.80 | 0.98 | 0.71 |
| R&D / Revenue | 330.4% | 504.4% | 672.5% | 482.0% | 398.0% |
| SG&A / Revenue | 289.8% | 388.3% | 639.8% | 450.2% | 245.1% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -89.9% | -151.2% | -51.3% | -67.4% | -24.2% |
| Return on equity | -317.4% | -816.5% | -77.6% | -74.8% | -26.3% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 4.53 | 0.93 | 7.59 | 9.25 | 15.15 |
| Quick ratio | 2.95 | 0.58 | 7.37 | 8.96 | 15.02 |
| Cash ratio | 2.55 | 0.40 | 7.11 | 8.48 | 14.65 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -9.3x | -11.1x | -87.7x | -861.6x | -552.3x |
| Equity multiplier | 3.53 | 5.40 | 1.51 | 1.11 | 1.09 |
| Liabilities / Assets | 0.72 | 0.81 | 0.34 | 0.10 | 0.08 |
| Efficiency | |||||
| Asset turnover | 0.11 | 0.13 | 0.04 | 0.07 | 0.04 |
| Inventory turnover | 0.15 | 0.18 | 0.57 | 1.01 | 1.47 |
| Days sales outstanding | 98d | 109d | 34d | 23d | 30d |
| Days inventory outstanding | 2402d | 2041d | 641d | 361d | 248d |
| Days payable outstanding | 766d | 951d | 1093d | 422d | 530d |
| Cash conversion cycle | 1734d | 1199d | -418d | -38d | -253d |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | 40.8% | 52.0% | -11.1% | 16.2% | - |
| Revenue CAGR (3y) | 23.9% | 16.2% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | 31.1% | 56.7% | -9.5% | 4.5% | - |
| Operating income growth (YoY) | 1.1% | -22.6% | -25.1% | -67.3% | - |
| Net income growth (YoY) | 1.0% | -32.1% | -25.0% | -64.8% | - |
| EPS growth (YoY) | 44.7% | 8.6% | 3.1% | 86.7% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 4.9% | -76.9% | -2.6% | -125.4% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 154.7% | -87.4% | 20.4% | -42.1% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$2.29M totalBusiness Segment$2.29M · 100.0%
Geographic
$2.29M totalUS$1.39M · 60.8%
Non Us$899.8K · 39.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-7.88
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing FEMASYS INC against the 5 most active filers in the same SIC group.